Nanjing Immunophage Biomedical Co., Ltd. (“Immunophage”) has been officially named a newly accredited foreign-funded R&D center in the 2026 list released by the Nanjing Municipal Science and Technology Bureau. Immunophage is one of the six enterprises selected from the Nanjing Jiangbei New Area.
Immunophage has been based in the Nanjing Biotech and Pharmaceutical Valley in the Jiangbei New Area since 2016. The Company focuses on major diseases, including autoimmune diseases, oncological diseases, and neurodegenerative diseases, and is dedicated to the discovery and development of first-in-class drugs. To date, Immunophage has filed over a dozen PCT patent applications and been granted more than 40 invention patents, building core R&D capabilities in immune-metabolic regulation and GPCR targets.
The Company has 7 pipeline programs, with multiple drug candidates in clinical development, continuously advancing the translation of original research into clinical application.
This foreign-funded R&D center accreditation represents significant recognition of the Company's R&D system and technical capabilities by municipal and district authorities. Immunophage will continue to leverage the industrial ecosystem of the Biotech and Pharmaceutical Valley, remain deeply rooted in Nanjing, and drive original innovation to deliver breakthrough therapies to patients.
About Immunophage
Nanjing Immunophage Biomedical Co., Ltd. was founded in 2016. It is a clinical-stage biopharmaceutical company based in China with a global outlook, dedicated to developing first-in-class new drugs for major diseases, including autoimmune diseases, malignant tumors, and neurodegenerative diseases. Immunophage has granted more than 40 invention patents. There are 7 pipeline programs, with novel drug candidates including IPG11406, IPG1094, IPG7236, IPG8294, and others now in clinical development. The Company is a National High-Tech Enterprise, a Jiangsu Provincial Emerging Enterprise, and a Nanjing Municipal Foreign-Funded R&D Center. It has received key support from the Jiangsu Provincial "Innovation and Entrepreneurship Program," been recognized as a "Jiangsu Provincial Potential Unicorn Enterprise," honored as a "Most Valuable Investment Enterprise in China," and consistently listed among the Top 100 Innovative Enterprises in the Chinese biopharmaceutical industry.
